Regulation of the Complement System by Pentraxins.
CRP–C-reactive protein
PTX3
age-related macular degeneration (AMD)
cholesterol
complement C1q
complement factor H
factor H-related protein
innate
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
06
2019
accepted:
10
07
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
The functions of pentraxins, like C-reactive protein (CRP), serum amyloid protein P (SAP) and pentraxin-3 (PTX3), are to coordinate spatially and temporally targeted clearance of injured tissue components, to protect against infections and to regulate related inflammation together with the complement system. For this, pentraxins have a dual relationship with the complement system. Initially, after a focused binding to their targets, e.g., exposed phospholipids or cholesterol in the injured tissue area, or microbial components, the pentraxins activate complement by binding its first component C1q. However, the emerging inflammation needs to be limited to the target area. Therefore, pentraxins inhibit complement at the C3b stage to prevent excessive damage. The complement inhibitory functions of pentraxins are based on their ability to interact with complement inhibitors C4bp or factor H (FH). C4bp binds to SAP, while FH binds to both CRP and PTX3. FH promotes opsonophagocytosis through inactivation of C3b to iC3b, and inhibits AP activity thus preventing formation of the C5a anaphylatoxin and the complement membrane attack complex (MAC). Monitoring CRP levels gives important clinical information about the extent of tissue damage and severity of infections. CRP is a valuable marker for distinguishing bacterial infections from viral infections. Disturbances in the functions and interactions of pentraxins and complement are also involved in a number of human diseases. This review will summarize what is currently known about the FH family proteins and pentraxins that interact with FH. Furthermore, we will discuss diseases, where interactions between these molecules may play a role.
Identifiants
pubmed: 31428091
doi: 10.3389/fimmu.2019.01750
pmc: PMC6688104
doi:
Substances chimiques
Complement Membrane Attack Complex
0
Serum Amyloid P-Component
0
PTX3 protein
148591-49-5
Complement Factor H
80295-65-4
Complement System Proteins
9007-36-7
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750Références
J Immunol. 1999 Oct 1;163(7):3957-62
pubmed: 10490997
J Immunol. 1999 Oct 15;163(8):4590-6
pubmed: 10510403
Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2348-54
pubmed: 10521363
Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72
pubmed: 1067618
FASEB J. 2000 May;14(7):835-46
pubmed: 10783137
N Engl J Med. 2000 Oct 19;343(16):1139-47
pubmed: 11036119
J Exp Med. 2000 Nov 6;192(9):1353-64
pubmed: 11067883
Am J Hum Genet. 2001 Feb;68(2):485-90
pubmed: 11170896
N Engl J Med. 2001 Apr 5;344(14):1058-66
pubmed: 11287977
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13043-8
pubmed: 12244213
J Immunol. 2002 Nov 1;169(9):4702-6
pubmed: 12391176
Trends Immunol. 2003 Mar;24(3):148-54
pubmed: 12615211
Eur J Immunol. 2003 Apr;33(4):962-9
pubmed: 12672062
J Med Genet. 2003 Sep;40(9):676-81
pubmed: 12960213
Science. 1954 Aug 20;120(3112):279-85
pubmed: 13186838
J Exp Med. 1992 Apr 1;175(4):939-50
pubmed: 1532415
J Am Soc Nephrol. 2005 Feb;16(2):555-63
pubmed: 15590760
Science. 2005 Apr 15;308(5720):419-21
pubmed: 15761120
Science. 2005 Apr 15;308(5720):421-4
pubmed: 15761121
Science. 2005 Apr 15;308(5720):385-9
pubmed: 15761122
Biochem Biophys Res Commun. 2005 Apr 22;329(4):1208-16
pubmed: 15766555
Clin Chem. 2005 May;51(5):856-63
pubmed: 15774575
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32
pubmed: 15870199
J Immunol. 2005 May 15;174(10):6250-6
pubmed: 15879123
J Med Genet. 2006 Jul;43(7):582-9
pubmed: 16299065
Nat Genet. 2006 Oct;38(10):1173-7
pubmed: 16998489
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17456-61
pubmed: 17079491
J Immunol. 2007 Mar 15;178(6):3831-6
pubmed: 17339482
PLoS Genet. 2007 Mar 16;3(3):e41
pubmed: 17367211
Mol Immunol. 2007 Jul;44(13):3398-406
pubmed: 17399790
J Infect Dis. 2008 May 1;197(9):1244-53
pubmed: 18422436
J Biol Chem. 2008 Nov 7;283(45):30451-60
pubmed: 18786923
Nature. 2008 Dec 18;456(7224):989-92
pubmed: 19011614
J Immunol. 2008 Dec 15;181(12):8433-40
pubmed: 19050261
Mol Immunol. 2009 Jan;46(3):335-44
pubmed: 19084272
Cell Death Differ. 2009 Dec;16(12):1630-40
pubmed: 19680263
Annu Rev Immunol. 2010;28:157-83
pubmed: 19968561
Clin J Am Soc Nephrol. 2010 May;5(5):770-82
pubmed: 20185597
Trends Cardiovasc Med. 2009 Oct;19(7):232-7
pubmed: 20382347
Ophthalmology. 2010 Oct;117(10):1982-8
pubmed: 20605213
J Biol Chem. 2010 Sep 24;285(39):30192-202
pubmed: 20660596
Nat Genet. 2010 Sep;42(9):772-6
pubmed: 20694013
Atherosclerosis. 2010 Nov;213(1):184-90
pubmed: 20708732
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2897-902
pubmed: 21285368
Br J Ophthalmol. 2011 Sep;95(9):1323-30
pubmed: 21633121
FASEB J. 2011 Dec;25(12):4198-210
pubmed: 21856781
Acta Ophthalmol. 2012 Dec;90(8):695-703
pubmed: 22067048
J Immunol. 2012 Jan 1;188(1):426-35
pubmed: 22140259
Ageing Res Rev. 2012 Apr;11(2):189-98
pubmed: 22186030
J Immunol. 2012 Aug 15;189(4):1858-67
pubmed: 22786770
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4685-90
pubmed: 23487775
Am J Kidney Dis. 2013 Sep;62(3):506-14
pubmed: 23623956
J Invest Dermatol. 2014 Feb;134(2):498-506
pubmed: 23938460
Methods Mol Biol. 2014;1100:225-36
pubmed: 24218263
J Clin Invest. 2014 Jan;124(1):145-55
pubmed: 24334459
J Am Soc Nephrol. 2014 Nov;25(11):2425-33
pubmed: 24722444
Mol Immunol. 2014 Oct;61(2):118-125
pubmed: 25034031
J Immunol. 2014 Nov 15;193(10):4962-70
pubmed: 25305316
PLoS One. 2015 Mar 23;10(3):e0120757
pubmed: 25798599
J Immunol. 2015 May 15;194(10):4963-73
pubmed: 25855355
Trends Immunol. 2015 Jun;36(6):374-84
pubmed: 25979655
J Biol Chem. 2015 Nov 27;290(48):28977-87
pubmed: 26468283
Blood. 2016 Jun 2;127(22):2701-10
pubmed: 27006390
FEBS Lett. 2016 Aug;590(15):2418-34
pubmed: 27393384
Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20
pubmed: 276881
Immunol Rev. 2016 Nov;274(1):202-217
pubmed: 27782337
Eye Vis (Lond). 2016 Dec 22;3:34
pubmed: 28032115
Blood. 2017 May 25;129(21):2847-2856
pubmed: 28416508
J Immunol. 2017 Jul 1;199(1):292-303
pubmed: 28533443
Circ Cardiovasc Genet. 2017 Dec;10(6):null
pubmed: 29212897
Sci Rep. 2018 Jan 26;8(1):1643
pubmed: 29374201
J Immunol. 2018 Apr 1;200(7):2464-2478
pubmed: 29500241
J Exp Med. 1977 Jul 1;146(1):257-70
pubmed: 301546
Front Immunol. 2018 Nov 21;9:2701
pubmed: 30519244
Mol Immunol. 1986 Oct;23(10):1045-52
pubmed: 3099175
Adv Immunol. 1983;34:141-212
pubmed: 6356809
J Exp Med. 1981 Sep 1;154(3):856-67
pubmed: 6912277
J Immunol. 1981 May;126(5):1820-5
pubmed: 7217669
J Immunol. 1994 Mar 1;152(5):2430-7
pubmed: 8133054
Cytokine Growth Factor Rev. 1996 Aug;7(2):191-202
pubmed: 8899296
J Immunol. 1996 Dec 15;157(12):5422-7
pubmed: 8955190
J Biol Chem. 1997 Dec 26;272(52):32817-23
pubmed: 9407058
Biochem J. 1998 Apr 1;331 ( Pt 1):41-7
pubmed: 9512460
Kidney Int. 1998 Apr;53(4):836-44
pubmed: 9551389